Last10K.com

Respirerx Pharmaceuticals Inc. (RSPI) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Respirerx Pharmaceuticals Inc.

CIK: 849636 Ticker: RSPI
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2015
Mar. 23, 2016
Jun. 30, 2015
Document And Entity Information   
Entity Registrant NameRespireRx Pharmaceuticals Inc.  
Entity Central Index Key0000849636  
Document Type10-K  
Document Period End DateDec. 31, 2015  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusNo  
Entity Voluntary FilerYes  
Entity Filer CategorySmaller Reporting Company  
Entity Public Float  $ 5,454,000
Entity Common Stock, Shares Outstanding 498,622,133 
Trading SymbolRSPI  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2015  

View differences made from one year to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..

Continue

Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (parenthetical)
Consolidated Statements Of Operations
Consolidated Statements Of Operations (parenthetical)
Consolidated Statements Of Stockholders' Deficiency
Consolidated Statements Of Stockholders' Deficiency (parenthetical)
Commitments And Contingencies
Commitments And Contingencies (details Narrative)
Commitments And Contingencies (tables)
Commitments And Contingencies - Schedule Of Principal Cash Obligations And Commitments (details)
Income Taxes
Income Taxes (details Narrative)
Income Taxes (tables)
Income Taxes - Reconciliation Of Income Tax Rate Federal Statutory Rate And Effective Tax Rate (details)
Income Taxes - Schedule Of Deferred Tax Assets (details)
Notes Payable
Notes Payable (details Narrative)
Notes Payable (tables)
Notes Payable - Schedule Of Convertible Notes Payable (details)
Notes Payable - Summary Of Note Payable To Related Party (details)
Organization And Business
Organization And Business (details Narrative)
Project Advance
Project Advance (details Narrative)
Related Party Transactions
Related Party Transactions (details Narrative)
Settlements
Settlements (details Narrative)
Stockholders' Deficiency
Stockholders' Deficiency (details Narrative)
Stockholders' Deficiency (tables)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Options Outstanding And Exercisable (details)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Warrants Outstanding And Exercisable (details)
Stockholders' Deficiency - Schedule Of Stock Options Activity (details)
Stockholders' Deficiency - Schedule Of Warrants Activity (details)
Subsequent Events
Subsequent Events (details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details Narrative)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (details)
Summary Of Significant Accounting Policies - Summary Of Fair Value Of Option Estimated Using Black-scholes Pricing Model With Valuation Assumptions (details)
Ticker: RSPI
CIK: 849636
Form Type: 10-K Annual Report
Accession Number: 0001493152-16-008331
Submitted to the SEC: Tue Mar 29 2016 8:37:39 AM EST
Accepted by the SEC: Tue Mar 29 2016
Period: Thursday, December 31, 2015
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rspi/0001493152-16-008331.htm